Avner Hershlag, M.D., F.A.C.OG.
Dr. Hershlag is board-certified in Obstetrics and Gynecology and Reproductive Endocrinology. He served as the Program Director, Reproductive Endocrinology and Infertility Fellowship of the Fertility Center at Northwell Health, providing fertility services to the Greater New York region. He served as the Chief of Northwell Fertility between 2011-2018.
He has cared for patients for more than 25 years and established successful programs at the center, including: Third Party Reproduction, Preimplantation Genetic Testing (PGT), Egg Freezing, and Fertility Preservation for cancer patients. Dr. Hershlag is an attending physician in the Department of Obstetrics and Gynecology at North Shore University Hospital. He holds a faculty appointment as Professor of Obstetrics, Gynecology, and Reproductive Medicine at the Hofstra Northwell School of Medicine.
Dr. Hershlag completed his undergraduate and graduate education training in his native country, Israel, and graduated from the Hadassah Medical School in Jerusalem. While in medical school, Dr. Hershlag was elected Director of Medical Education of the International Federation of Medical Students Society (IFMSA). Following three years of a General Surgery residency at Hadassah, Dr. Hershlag moved to the United States in 1984. Here, he completed his Ob-Gyn residency at the George Washington University Medical Center and a fellowship in Reproductive Endocrinology at Yale University School of Medicine.
Dr. Hershlag has developed a rigorous research program at the center, with several ongoing research projects. His research now focuses on the impact of genetics on infertility, as well as fertility preservation and prevention of cancer through genetic screening and PGT. He is also invested in access to fertility care and the ethics of reproductive technologies. He is a past member of the board of directors of RESOLVE: The National Infertility Association. Dr. Hershlag is the author of sixty original papers, over 30 book chapters, and a novel entitled, Misconception. He is the recipient of several awards including Castle Connolly’s Top Doctors over the past several years and is a professor of Ob/Gyn and Reproductive Medicine at Hofstra School of Medicine.
“The potential impact of tumor suppressor genes on human gametogenesis: a case control study”
Do infertility patients have an increased risk to harbor cancer genes? Dr. Avner Hershlag, a world-renowned leader in the field, and his team, sought to answer this question. Their findings were just published by the Journal of Assisted Reproduction and Genetics. Indeed, several cancer genes were found in women with low egg reserve and in males with low or no sperm. Could cancer genes be the culprit in some cases of infertility? Do some infertile men and women have a higher chance to develop cancer? Further, larger scale studies may shed further light on this association. Read the study.
“Comparing ethnicity-based and expanded carrier screening methods at a single fertility center reveals significant differences in carrier rates and carrier couple rates”
Expanded Carrier Screening (ECS) has become the standard of care for patients seeking fertility treatment over traditional ethnicity-based genetic screening panels. Due to the increased liklihood that individuals seek to become single parents, not knowing the genetic status of their donation partner, and the recent developments of cost-effective genomic technologies, genetic screenings have become increasingly accessible. New York Reproductive’s Dr. Avner Hershlag co-authors this study comparing the effectiveness ethnicity-based carrier screening and the newer expanded carrier screening to ensure a healthy, live birth baby. Read the study.
“Choosing an expanded carrier screening panel: comparing two panels at a single fertility centre”
Dr. Avner Hershlag investigates Carrier rates and carrier couple rates and their increases as expanded carrier screening panels (ECS panels) include more disorders and mutations. These rates, however, vary based on self-reported ethinicity. Preconception carrier screening of a diverse ethic population benefits from a more broadened and comprehensive expended carrier screening panel. Read the study.